• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Invitae | Genelex

Invitae | Genelex

Pharmacogenetics Makes Precision Medicine Possible

  • For Patients
    • Conditions
    • Affected Drugs
    • What is PGx?
    • Resources
    • FAQs
  • For Providers
    • Conditions
    • Resources
    • Order Testing Supplies
  • Test Menu
  • Clinical Trials
  • About
    • Lab Accreditations
    • Genelex Team
    • Contact Us
  • Log In
Home / Patients / Conditions / Cancer

CONDITIONS

Pharmacogenetics and Cancer

Cancer

Depression

Epilepsy

Cardiovascular

Chronic Pain

Diabetes

HIV

Acid Reflux

Precision medication management, including DNA testing, is extremely important for the proper treatment of cancer — finding the right drug and dose is vital. Over half of all medications, including the majority of cancer medications, are metabolized by three enzymes in the liver: CYP2D6, CYP2C9, and CYP2C19. Other metabolic pathways include CYP1A2, DPYD, NAT2, UGT1A, and TPMT. [4]

Your genes are the main factor in determining the level of these enzymes primarily found in your liver.

If you have too much of an enzyme, you process the medication too quickly. Too little of the enzyme and the medication builds up in your bloodstream potentially causing adverse reactions or side effects.

Without a clear picture of your genetic makeup, your physician may need to go through months of trial-and-error prescribing to find the right drug and dose for you.

PGx FOR CANCER PATIENTS

Discover the Right Cancer Treatment, Faster

Genelex pharmacogenetic testing complements current efforts to optimize treatment of cancer and leads towards effective and personalized care — all while being more cost effective and reducing trial-and-error efforts.

With advances in genetics, you are now able to optimize your response to cancer drugs and many other medications through DNA testing. In partnership with YouScript, a leader in drug-drug and drug-gene interaction software, you'll get a report highlighting patient-specific genetic markers and potential interactions, allowing for drug and dosage decisions to be catered to your needs.

Read below for more specific information on how different oncology pharmaceuticals are impacted by variations in your genes.

Population Frequency of Cytochrome P450 Metabolizer Types [5]

Poor Metabolizer Intermediate Metabolizer Normal Metabolizer Rapid or Ultra Rapid Metabolizer
CYP2D6* 4-7% 9-35% 50-90% 2-3%
CYP2C9 3% 30% 68% N/A
CYP2C19* 2-20% 24-36% 14-44% 30%

*CYP2C19 variability depends on ethnicity.
*CYP2D6 Variability depends on ethnicity and classification of Intermediate activity

Some cancer medications and involved metabolic pathways include:[6]

TRADE NAMEDRUGGENE
Adrucil®fluorouracilDYPD
Beleodaq®belinstatUGT1A1
Camptosar®irinotecanUGT1A1
Iressa®gefitinibCYP2D6
Lanvis®thioguanineTPMT
Nolvadex®tamoxifenCYP2D6
Platinol®cisplatinTPMT
Purixan®mercaptopurineTPMT
Quinamed®amonafideNAT2
Rubraca®rucaparibCYP1A2, CYP2D6
Tasigna®niloinibUGT1A1
Votrient®pazopanibUGT1A1
Xeloda®capecitabineDYPD

Patient Resources

Understanding Your Results
Insurance Information
Talking to Your Healthcare Provider
Requisition Form
Frequently Asked Questions
Genelex Blog

Improving Drug Efficacy

Genelex's pharmacogenetic testing bridges the gap in understanding how the role of PGx can help in patient care and offers a simple DNA test and provides you with a report of the results that you and your doctor can discuss.

Footer

CONTACT US

(800) 837-8362
info@genelex.com

3101 Western Ave.
Suite 100
Seattle, WA 98121

HELPFUL INFORMATION

What is PGx?
Test Menu
Conditions
Affected Drugs
FAQs
References

ABOUT GENELEX

Blog
News
Genelex Team
Lab Accreditations
Contact Us
Privacy Practices
Privacy Policy

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

KEEP IN TOUCH

Stay in the loop with news and updates from Genelex and be among the first to know when new tests become available.